{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:02:51Z","timestamp":1794265371352,"version":"4.9.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2001090"],"award-info":[{"award-number":["GNT2001090"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Future Fund","award":["MRF1201204"],"award-info":[{"award-number":["MRF1201204"]}]},{"DOI":"10.13039\/501100020598","name":"MSWA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020598","id-type":"DOI","asserted-by":"crossref"}]},{"name":"McCusker Charitable Research Foundation"},{"name":"Wen Giving Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood\u2013brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevention and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showcasing its remarkable antioxidative and anti-inflammatory properties, its ability to fortify the BBB and its direct influence on neural preservation and adaptability. These diverse effects collectively translate into enhancements in both motor and cognitive functions. This review provides a comprehensive overview of recent findings highlighting the efficacy of probucol and probucol-related compounds in the context of various neurodegenerative conditions, including Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease, and cognitive impairment associated with diabetes.<\/jats:p>","DOI":"10.1186\/s40035-024-00398-w","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T23:37:39Z","timestamp":1705880259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases"],"prefix":"10.1186","volume":"13","author":[{"given":"Arazu","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Mooranian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Clarnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-3382","authenticated-orcid":false,"given":"Ryu","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","first-page":"754204","DOI":"10.3389\/fneur.2021.754204","volume":"12","author":"A Brodtmann","year":"2021","unstructured":"Brodtmann A, Werden E, Khlif MS, Bird LJ, Egorova N, Veldsman M, et al. Neurodegeneration over 3 years following ischaemic stroke: findings from the cognition and neocortical volume after stroke study. Front Neurol. 2021;12:754204.","journal-title":"Front Neurol"},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.bbadis.2016.06.015","volume":"1863","author":"SK Jha","year":"2017","unstructured":"Jha SK, Jha NK, Kumar D, Ambasta RK, Kumar P. Linking mitochondrial dysfunction, metabolic syndrome and stress signaling in neurodegeneration. Biochim Biophys Acta (BBA) Mol Basis Dis. 2017;1863:1132\u201346.","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Dis"},{"key":"398_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/med.21794","volume":"41","author":"AY Abramov","year":"2021","unstructured":"Abramov AY, Bachurin SO. Neurodegenerative disorders: searching for targets and new ways of diseases treatment. Med Res Rev. 2021;41:2603\u20135.\u00a0","journal-title":"Med Res Rev"},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"624919","DOI":"10.3389\/fimmu.2021.624919","volume":"12","author":"LG de Oliveira","year":"2021","unstructured":"de Oliveira LG, Angelo YS, Iglesias AH, Peron JPS. Unraveling the link between mitochondrial dynamics and neuroinflammation. Front Immunol. 2021;12:624919.","journal-title":"Front Immunol"},{"key":"398_CR5","doi-asserted-by":"publisher","first-page":"101755","DOI":"10.1016\/j.redox.2020.101755","volume":"37","author":"P Malko","year":"2020","unstructured":"Malko P, Jiang LH. TRPM2 channel-mediated cell death: an important mechanism linking oxidative stress-inducing pathological factors to associated pathological conditions. Redox Biol. 2020;37:101755.","journal-title":"Redox Biol"},{"key":"398_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/cdd.2014.150","volume":"22","author":"G Filomeni","year":"2015","unstructured":"Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22:377\u201388.","journal-title":"Cell Death Differ"},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"128434","DOI":"10.3389\/fncel.2015.00028","volume":"9","author":"R Sankowski","year":"2015","unstructured":"Sankowski R, Mader S, Vald\u00e9s-Ferrer SI. Systemic inflammation and the brain: Novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:128434.","journal-title":"Front Cell Neurosci"},{"key":"398_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1096\/fj.05-3776fje","volume":"19","author":"JP Godbout","year":"2005","unstructured":"Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. 2005;19:1329\u201331.","journal-title":"FASEB J"},{"key":"398_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.redox.2018.01.008","volume":"15","author":"JN Cobley","year":"2018","unstructured":"Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490\u2013503.","journal-title":"Redox Biol"},{"key":"398_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2009.04.002","volume":"207","author":"S Yamashita","year":"2009","unstructured":"Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009;207:16\u201323.","journal-title":"Atherosclerosis"},{"key":"398_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/archinte.1981.00340080138037","volume":"141","author":"L Klein","year":"1981","unstructured":"Klein L. QT-interval prolongation produced by probucol. Arch Intern Med. 1981;141:1102\u20133.","journal-title":"Arch Intern Med"},{"key":"398_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0021-9150(99)00493-1","volume":"152","author":"A Adlouni","year":"2000","unstructured":"Adlouni A, ElMessal M, Sa\u00efle R, Parra HJ, Fruchart JC, Ghalim N. Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. Atherosclerosis. 2000;152:433\u201340.","journal-title":"Atherosclerosis"},{"key":"398_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1046\/j.1365-2362.1997.1040657.x","volume":"27","author":"M Ishigami","year":"1997","unstructured":"Ishigami M, Yamashita S, Sakai N, Hirano KI, Arai T, Maruyama T, et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997;27:285\u201392.","journal-title":"Eur J Clin Invest"},{"key":"398_CR14","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.ATV.0000185834.98941.3d","volume":"25","author":"KI Hirano","year":"2005","unstructured":"Hirano KI, Ikegami C, Tsujii KI, Zhang Z, Matsuura F, Nakagawa-Toyama Y, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol. 2005;25:2422\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"398_CR15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1161\/01.ATV.19.5.1325","volume":"19","author":"F Rinninger","year":"1999","unstructured":"Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19:1325\u201332.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5551\/jat.ED155","volume":"28","author":"KI Hirata","year":"2021","unstructured":"Hirata KI. New evidence of probucol on cardiovascular events. J Atheroscler Thromb. 2021;28:97.","journal-title":"J Atheroscler Thromb"},{"key":"398_CR17","first-page":"7","volume":"0","author":"AD Wong","year":"2013","unstructured":"Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC. The blood-brain barrier: an engineering perspective. Front Neuroeng. 2013;0:7.","journal-title":"Front Neuroeng"},{"key":"398_CR18","unstructured":"Daneman R, Prat A. The Blood\u2013brain barrier. http:\/\/cshperspectives.cshlp.org\/. Accessed 19 Jan 2022"},{"key":"398_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nn2073","volume":"11","author":"Z Zhong","year":"2008","unstructured":"Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O\u2019Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11:420\u20132.","journal-title":"Nat Neurosci"},{"key":"398_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ana.24406","volume":"78","author":"J Drouin-Ouellet","year":"2015","unstructured":"Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagac\u00e9 M, Kuan WL, Saint-Pierre M, et al. Cerebrovascular and blood\u2013brain barrier impairments in Huntington\u2019s disease: potential implications for its pathophysiology. Ann Neurol. 2015;78:160\u201377.","journal-title":"Ann Neurol"},{"key":"398_CR21","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/brain\/awz011","volume":"142","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Shinohara M, Shinohara M, Yamazaki A, Murray ME, Liesinger AM, et al. Selective loss of cortical endothelial tight junction proteins during Alzheimer\u2019s disease progression. Brain. 2019;142:1077\u201392.","journal-title":"Brain"},{"key":"398_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.14336\/AD.2018.0720","volume":"10","author":"K Li","year":"2019","unstructured":"Li K, Li J, Zheng J, Qin S. Reactive astrocytes in neurodegenerative diseases. Aging Dis. 2019;10:664.","journal-title":"Aging Dis"},{"key":"398_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/bpa.12888","volume":"30","author":"R Ding","year":"2020","unstructured":"Ding R, Hase Y, Ameen-Ali KE, Ndung\u2019u M, Stevenson W, Barsby J, et al. Loss of capillary pericytes and the blood-brain barrier in white matter in poststroke and vascular dementias and Alzheimer\u2019s disease. Brain Pathol. 2020;30:1087\u2013101.","journal-title":"Brain Pathol"},{"key":"398_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","volume":"36","author":"MR Halliday","year":"2016","unstructured":"Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2016;36:216\u201327.","journal-title":"J Cereb Blood Flow Metab"},{"key":"398_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ana.24428","volume":"78","author":"HY Hsiao","year":"2015","unstructured":"Hsiao HY, Chen YC, Huang CH, Chen CC, Hsu YH, Chen HM, et al. Aberrant astrocytes impair vascular reactivity in Huntington disease. Ann Neurol. 2015;78:178\u201392.","journal-title":"Ann Neurol"},{"key":"398_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/jcbfm.2015.32","volume":"35","author":"MT Gray","year":"2015","unstructured":"Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson\u2019s disease. J Cereb Blood Flow Metab. 2015;35:747\u201350.","journal-title":"J Cereb Blood Flow Metab"},{"key":"398_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.brainres.2007.04.044","volume":"1157","author":"S Garbuzova-Davis","year":"2007","unstructured":"Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR. Ultrastructure of blood\u2013brain barrier and blood\u2013spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126\u201337.","journal-title":"Brain Res"},{"key":"398_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nn.3966","volume":"18","author":"EA Winkler","year":"2015","unstructured":"Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, et al. GLUT1 reductions exacerbate Alzheimer\u2019s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015;18:521\u201330.","journal-title":"Nat Neurosci"},{"key":"398_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.brainres.2017.10.035","volume":"1678","author":"P Vogelsang","year":"2018","unstructured":"Vogelsang P, Giil LM, Lund A, Vedeler CA, Parkar AP, Nordrehaug JE, et al. Reduced glucose transporter-1 in brain derived circulating endothelial cells in mild Alzheimer\u2019s disease patients. Brain Res. 2018;1678:304\u20139.","journal-title":"Brain Res"},{"key":"398_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00401-006-0115-3","volume":"112","author":"JE Donahue","year":"2006","unstructured":"Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer\u2019s disease. Acta Neuropathol. 2006;112:405\u201315.","journal-title":"Acta Neuropathol"},{"key":"398_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"S du Yan","year":"1996","unstructured":"du Yan S, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-\u03b2 peptide neurotoxicity in Alzheimer\u2019s disease. Nature. 1996;382:685\u201391.","journal-title":"Nature"},{"key":"398_CR32","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.neurobiolaging.2015.05.020","volume":"36","author":"C Chiu","year":"2015","unstructured":"Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer\u2019s disease: preliminary observations. Neurobiol Aging. 2015;36:2475\u201382.","journal-title":"Neurobiol Aging"},{"key":"398_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12035-019-01844-x","volume":"57","author":"S Nakagawa","year":"2019","unstructured":"Nakagawa S, Aruga J. Sphingosine 1-phosphate signaling is involved in impaired blood\u2013brain barrier function in ischemia-reperfusion injury. Mol Neurobiol. 2019;57:1594\u2013606.","journal-title":"Mol Neurobiol"},{"key":"398_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000355825","volume":"23","author":"B Takase","year":"2014","unstructured":"Takase B, Nagata M, Hattori H, Tanaka Y, Ishihara M. Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. Med Principles Pract. 2014;23:59\u201365.","journal-title":"Med Principles Pract"},{"key":"398_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12031-015-0635-1","volume":"57","author":"J Ma","year":"2015","unstructured":"Ma J, Zhao S, Gao G, Chang H, Ma P, Jin B. Probucol protects against asymmetric dimethylarginine-induced apoptosis in the cultured human brain microvascular endothelial cells. J Mol Neurosci. 2015;57:546\u201353.","journal-title":"J Mol Neurosci"},{"key":"398_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ejcb.2005.03.002","volume":"84","author":"S Fischer","year":"2005","unstructured":"Fischer S, Wiesnet M, Renz D, Schaper W. H2O2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44\/42 MAP kinase pathway. Eur J Cell Biol. 2005;84:687\u201397.","journal-title":"Eur J Cell Biol"},{"key":"398_CR37","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/jcbfm.2010.29","volume":"30","author":"JJ Lochhead","year":"2010","unstructured":"Lochhead JJ, McCaffrey G, Quigley CE, Finch J, Demarco KM, Nametz N, et al. Oxidative stress increases blood\u2013brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab. 2010;30:1625\u201336.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"297","key":"398_CR38","first-page":"1186","volume":"2002","author":"Z Gu","year":"1979","unstructured":"Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 1979;2002(297):1186\u201390.","journal-title":"Science"},{"key":"398_CR39","doi-asserted-by":"crossref","unstructured":"Song K, Li Y, Zhang H, An N, Wei Y, Wang L, et al. Oxidative stress-mediated blood\u2013brain barrier (BBB) disruption in neurological diseases. Oxid Med Cell Longev. 2020;2020.","DOI":"10.1155\/2020\/4356386"},{"key":"398_CR40","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/cns.13101","volume":"25","author":"W Chen","year":"2019","unstructured":"Chen W, Ju XZ, Lu Y, Ding XW, Miao CH, Chen JW. Propofol improved hypoxia-impaired integrity of blood-brain barrier via modulating the expression and phosphorylation of zonula occludens-1. CNS Neurosci Ther. 2019;25:704\u201313.","journal-title":"CNS Neurosci Ther"},{"key":"398_CR41","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1096\/fj.201801595RR","volume":"33","author":"S Tan","year":"2019","unstructured":"Tan S, Shan Y, Lin Y, Liao S, Zhang B, Zeng Q, et al. Neutralization of interleukin-9 ameliorates experimental stroke by repairing the blood-brain barrier via down-regulation of astrocyte-derived vascular endothelial growth factor-A. FASEB J. 2019;33:4376\u201387.","journal-title":"FASEB J"},{"key":"398_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jneumeth.2014.03.002","volume":"228","author":"J Labus","year":"2014","unstructured":"Labus J, H\u00e4ckel S, Lucka L, Danker K. Interleukin-1\u03b2 induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain barrier model. J Neurosci Methods. 2014;228:35\u201345.","journal-title":"J Neurosci Methods"},{"key":"398_CR43","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1016\/j.febslet.2011.04.066","volume":"585","author":"C Larochelle","year":"2011","unstructured":"Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585:3770\u201380.","journal-title":"FEBS Lett"},{"key":"398_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.yexcr.2018.10.002","volume":"373","author":"J Labus","year":"2018","unstructured":"Labus J, W\u00f6ltje K, Stolte KN, H\u00e4ckel S, Kim KS, Hildmann A, et al. IL-1\u03b2 promotes transendothelial migration of PBMCs by upregulation of the FN\/\u03b1 5 \u03b2 1 signalling pathway in immortalised human brain microvascular endothelial cells. Exp Cell Res. 2018;373:99\u2013111.","journal-title":"Exp Cell Res"},{"key":"398_CR45","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41593-017-0010-3","volume":"20","author":"C Menard","year":"2017","unstructured":"Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, et al. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 2017;20:1752\u201360.","journal-title":"Nat Neurosci"},{"key":"398_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1440-1681.12032","volume":"40","author":"R Takechi","year":"2013","unstructured":"Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Dhaliwal SS, Mamo JC. Probucol prevents blood\u2013brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. Clin Exp Pharmacol Physiol. 2013;40:45\u201352.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"398_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-511X-13-91","volume":"13","author":"R Takechi","year":"2014","unstructured":"Takechi R, Pallebage-Gamarallage MM, Lam V, Giles C, Mamo JC. Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction. Lipids Health Dis. 2014;13:1\u201310.","journal-title":"Lipids Health Dis"},{"issue":"Suppl","key":"398_CR48","first-page":"1","volume":"34","author":"SW Pimplikar","year":"2014","unstructured":"Pimplikar SW. Neuroinflammation in Alzheimer\u2019s disease: from pathogenesis to a therapeutic target. J Clin Immunol. 2014;34(Suppl):1.","journal-title":"J Clin Immunol"},{"key":"398_CR49","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","volume":"18","author":"EC Hirsch","year":"2012","unstructured":"Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18:S210\u20132.","journal-title":"Parkinsonism Relat Disord"},{"key":"398_CR50","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","volume":"117","author":"T M\u00f6ller","year":"2010","unstructured":"M\u00f6ller T. Neuroinflammation in Huntington\u2019s disease. J Neural Transm. 2010;117:1001\u20138.","journal-title":"J Neural Transm"},{"key":"398_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1479164118795274","volume":"16","author":"JCL Mamo","year":"2019","unstructured":"Mamo JCL, Lam V, Brook E, Mooranian A, Al-Salami H, Fimognari N, et al. Probucol prevents blood\u2013brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diab Vasc Dis Res. 2019;16:87\u201397.","journal-title":"Diab Vasc Dis Res"},{"key":"398_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0306-4522(03)00361-0","volume":"121","author":"D Champagne","year":"2003","unstructured":"Champagne D, Pearson D, Dea D, Rochford J, Poirier J. The cholesterol-lowering drug Probucol increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer\u2019s disease. Neuroscience. 2003;121:99\u2013110.","journal-title":"Neuroscience"},{"key":"398_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jns.2015.12.004","volume":"360","author":"P Talwar","year":"2016","unstructured":"Talwar P, Sinha J, Grover S, Agarwal R, Kushwaha S, Srivastava MVP, et al. Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. J Neurol Sci. 2016;360:179\u201387.","journal-title":"J Neurol Sci"},{"key":"398_CR54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1124\/jpet.106.118612","volume":"321","author":"BJ Wu","year":"2007","unstructured":"Wu BJ, di Girolamo N, Beck K, Hanratty CG, Choy K, Hou JY, et al. Probucol [4,4\u2032-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2007;321:477\u201384.","journal-title":"J Pharmacol Exp Ther"},{"key":"398_CR55","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/aps.2016.51","volume":"37","author":"YS Jung","year":"2016","unstructured":"Jung YS, Park JH, Kim H, Kim SY, Hwang JY, Hong KW, et al. Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice. Acta Pharmacol Sin. 2016;37:1031\u201344.","journal-title":"Acta Pharmacol Sin"},{"key":"398_CR56","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.3390\/ijms14036306","volume":"14","author":"S Bolisetty","year":"2013","unstructured":"Bolisetty S, Jaimes EA. Mitochondria and reactive oxygen species: physiology and pathophysiology. Int J Mol Sci. 2013;14:6306.","journal-title":"Int J Mol Sci"},{"key":"398_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0891-5849(95)02094-2","volume":"20","author":"RH Bisby","year":"1996","unstructured":"Bisby RH, Johnson SA, Parker AW. Quenching of reactive oxidative species by probucol and comparison with other antioxidants. Free Radic Biol Med. 1996;20:411\u201320.","journal-title":"Free Radic Biol Med"},{"key":"398_CR58","doi-asserted-by":"publisher","first-page":"8542","DOI":"10.18632\/aging.102337","volume":"11","author":"J-L Huang","year":"2019","unstructured":"Huang J-L, Yu C, Su M, Yang S-M, Zhang F, Chen Y-Y, et al. Probucol, a \u201cnon-statin\u201d cholesterol-lowering drug, ameliorates D-galactose induced cognitive deficits by alleviating oxidative stress via Keap1\/Nrf2 signaling pathway in mice. Aging (Albany NY). 2019;11:8542.","journal-title":"Aging (Albany NY)"},{"key":"398_CR59","doi-asserted-by":"publisher","first-page":"52078","DOI":"10.18632\/oncotarget.19107","volume":"8","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Liu C, Chen S, Zhao H, Zhou K, Wang W, et al. Activation of the Nrf2\/ARE signaling pathway by probucol contributes to inhibiting inflammation and neuronal apoptosis after spinal cord injury. Oncotarget. 2017;8:52078.","journal-title":"Oncotarget"},{"key":"398_CR60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neuroscience.2016.05.019","volume":"329","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Chen S, Zhao H, Wang C, Gao K, Guo Y, et al. Probucol inhibits neural cell apoptosis via inhibition of mTOR signaling pathway after spinal cord injury. Neuroscience. 2016;329:193\u2013200.","journal-title":"Neuroscience"},{"key":"398_CR61","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1007\/s12035-020-01963-w","volume":"57","author":"DB Santos","year":"2020","unstructured":"Santos DB, Colle D, Moreira ELG, Santos AA, Hort MA, Santos K, et al. Probucol protects neuronal cells against peroxide-induced damage and directly activates glutathione peroxidase-1. Mol Neurobiol. 2020;57:3245\u201357.","journal-title":"Mol Neurobiol"},{"key":"398_CR62","doi-asserted-by":"publisher","first-page":"112266","DOI":"10.1016\/j.biopha.2021.112266","volume":"144","author":"Y Xie","year":"2021","unstructured":"Xie Y, Song A, Zhu Y, Jiang A, Peng W, Zhang C, et al. Effects and mechanisms of probucol on aging-related hippocampus-dependent cognitive impairment. Biomed Pharmacother. 2021;144:112266.","journal-title":"Biomed Pharmacother"},{"key":"398_CR63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JAD-2003-5302","volume":"5","author":"AP James","year":"2003","unstructured":"James AP, Pal S, Gennat HC, Vine DF, Mamo JCL. The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. J Alzheimers Dis. 2003;5:179\u201388.","journal-title":"J Alzheimers Dis"},{"key":"398_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000343211","volume":"12","author":"R Takechi","year":"2013","unstructured":"Takechi R, Pallebage-Gamarallage MM, Lam V, Giles C, Mamo JC. Aging-related changes in blood-brain barrier integrity and the effect of dietary fat. Neurodegener Dis. 2013;12:125\u201335.","journal-title":"Neurodegener Dis"},{"key":"398_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1162-9","volume":"18","author":"S Galloway","year":"2019","unstructured":"Galloway S, Takechi R, Nesbit M, Pallebage-Gamarallage MM, Lam V, Mamo JCL. The differential effects of fatty acids on enterocytic abundance of amyloid-beta. Lipids Health Dis. 2019;18:1\u20136.","journal-title":"Lipids Health Dis"},{"key":"398_CR66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1258\/acb.2008.007214","volume":"45","author":"JCL Mamo","year":"2008","unstructured":"Mamo JCL, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J. Plasma lipoprotein \u03b2-amyloid in subjects with Alzheimer\u2019s disease or mild cognitive impairment. Ann Clin Biochem. 2008;45:395\u2013403.","journal-title":"Ann Clin Biochem"},{"key":"398_CR67","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00418-009-0567-3","volume":"131","author":"R Takechi","year":"2009","unstructured":"Takechi R, Galloway S, Pallebage-Gamarallage M, Wellington C, Johnsen R, Mamo JC. Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP\/PS1 transgenic mice. Histochem Cell Biol. 2009;131:661\u20136.","journal-title":"Histochem Cell Biol"},{"key":"398_CR68","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/0304-3940(92)90531-B","volume":"134","author":"Y Namba","year":"1992","unstructured":"Namba Y, Tsuchiya H, Ikeda K. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer\u2019s disease. Neurosci Lett. 1992;134:264\u20136.","journal-title":"Neurosci Lett"},{"key":"398_CR69","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/exnr.1994.1044","volume":"126","author":"DL Sparks","year":"1994","unstructured":"Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like \u03b2-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88\u201394.","journal-title":"Exp Neurol"},{"key":"398_CR70","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.plipres.2009.10.004","volume":"49","author":"R Takechi","year":"2010","unstructured":"Takechi R, Galloway S, Pallebage-Gamarallage MMS, Lam V, Mamo JCL. Dietary fats, cerebrovasculature integrity and Alzheimer\u2019s disease risk. Prog Lipid Res. 2010;49:159\u201370.","journal-title":"Prog Lipid Res"},{"key":"398_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1440-1681.12032","volume":"40","author":"R Takechi","year":"2013","unstructured":"Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Dhaliwal SS, Mamo JC. Probucol prevents blood\u2013brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. Clin Exp Pharmacol Physiol. 2013;40:45\u201352.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"398_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11745-011-3595-4","volume":"47","author":"MM Pallebage-Gamarallage","year":"2012","unstructured":"Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S, Mamo JCL. Probucol suppresses enterocytic accumulation of amyloid-\u03b2 induced by saturated fat and cholesterol feeding. Lipids. 2012;47:27\u201334.","journal-title":"Lipids"},{"key":"398_CR73","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1161\/01.ATV.13.2.231","volume":"13","author":"JCL Mamo","year":"1993","unstructured":"Mamo JCL, Elsegood CL, Umeda Y, Hirano T, Redgrave TG. Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats. Arterioscler Thromb. 1993;13:231\u20139.","journal-title":"Arterioscler Thromb"},{"key":"398_CR74","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.expneurol.2011.11.036","volume":"233","author":"DB Santos","year":"2012","unstructured":"Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira ELG, et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid \u03b2 peptide in mice. Exp Neurol. 2012;233:767\u201375.","journal-title":"Exp Neurol"},{"key":"398_CR75","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform\u2013specific disruption of amyloid \u03b2 peptide clearance from mouse brain. J Clin Invest. 2008;118:4002\u201313.","journal-title":"J Clin Invest"},{"key":"398_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fnagi.2014.00093","volume":"6","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid-\u03b2 clearance in Alzheimer\u2019s disease. Front Aging Neurosci. 2014;6:93.","journal-title":"Front Aging Neurosci"},{"key":"398_CR77","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Xu H, Bu G. ApoE and A\u03b2 in Alzheimer\u2019s disease: accidental encounters or partners? Neuron. 2014;81:740\u201354.","journal-title":"Neuron"},{"key":"398_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1471-4159.2001.00047.x","volume":"76","author":"B Drouet","year":"2001","unstructured":"Drouet B, Fifre A, Pin\u00e7on-Raymond M, Vandekerckhove J, Rosseneu M, Gu\u00e9ant JL, et al. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-\u03b2 peptide. J Neurochem. 2001;76:117\u201327.","journal-title":"J Neurochem"},{"key":"398_CR79","doi-asserted-by":"publisher","first-page":"17882","DOI":"10.1021\/bi980550y","volume":"37","author":"H Naiki","year":"1998","unstructured":"Naiki H, Hasegawa K, Yamaguchi I, Nakamura H, Gejyo F, Nakakuki K. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer\u2019s beta-amyloid fibril formation in vitro. Biochemistry. 1998;37:17882\u20139.","journal-title":"Biochemistry"},{"key":"398_CR80","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.neuroscience.2014.10.019","volume":"284","author":"DB Santos","year":"2015","unstructured":"Santos DB, Colle D, Moreira ELG, Peres KC, Ribeiro RP, dos Santos AA, et al. Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. Neuroscience. 2015;284:590\u2013600.","journal-title":"Neuroscience"},{"key":"398_CR81","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.neurobiolaging.2014.03.037","volume":"35","author":"J Poirier","year":"2014","unstructured":"Poirier J, Miron J, Picard C, Gormley P, Th\u00e9roux L, Breitner J, et al. Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer\u2019s disease. Neurobiol Aging. 2014;35:S3-10.","journal-title":"Neurobiol Aging"},{"key":"398_CR82","doi-asserted-by":"publisher","first-page":"e058826","DOI":"10.1136\/bmjopen-2021-058826","volume":"12","author":"V Lam","year":"2022","unstructured":"Lam V, Clarnette R, Francis R, Bynevelt M, Watts G, Flicker L, et al. Efficacy of probucol on cognitive function in Alzheimer\u2019s disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). BMJ Open. 2022;12:e058826.","journal-title":"BMJ Open"},{"key":"398_CR83","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s11064-012-0965-0","volume":"38","author":"RP Ribeiro","year":"2013","unstructured":"Ribeiro RP, Moreira ELG, Santos DB, Colle D, dos Santos AA, Peres KC, et al. Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson\u2019s disease. Neurochem Res. 2013;38:660\u20138.","journal-title":"Neurochem Res"},{"issue":"7","key":"398_CR84","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/cells8070712","volume":"8","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Li R, Yang H. Mitophagy in Parkinson\u2019s disease: from pathogenesis to treatment. Cells. 2019;8(7):712.","journal-title":"Cells"},{"key":"398_CR85","doi-asserted-by":"publisher","first-page":"e3001977","DOI":"10.1371\/journal.pbio.3001977","volume":"21","author":"N Moskal","year":"2023","unstructured":"Moskal N, Visanji NP, Gorbenko O, Narasimhan V, Tyrrell H, Nash J, et al. An AI-guided screen identifies probucol as an enhancer of mitophagy through modulation of lipid droplets. PLoS Biol. 2023;21:e3001977. https:\/\/doi.org\/10.1371\/journal.pbio.3001977.","journal-title":"PLoS Biol"},{"key":"398_CR86","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1038\/cddis.2013.513","volume":"5","author":"A Ray","year":"2014","unstructured":"Ray A, Martinez BA, Berkowitz LA, Caldwell GA, Caldwell KA. Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson\u2019s model. Cell Death Dis. 2014;5:e984\u2013e984.","journal-title":"Cell Death Dis"},{"key":"398_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-014-0114-8","volume":"9","author":"T Vinther-Jensen","year":"2014","unstructured":"Vinther-Jensen T, Larsen IU, Hjermind LE, Budtz-J\u00f8rgensen E, Nielsen TT, N\u00f8rrem\u00f8lle A, et al. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington\u2019s disease. Orphanet J Rare Dis. 2014;9:1\u20139.","journal-title":"Orphanet J Rare Dis"},{"key":"398_CR88","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.brainresbull.2012.01.003","volume":"87","author":"D Colle","year":"2012","unstructured":"Colle D, Hartwig JM, Antunes Soares FA, Farina M. Probucol modulates oxidative stress and excitotoxicity in Huntington\u2019s disease models in vitro. Brain Res Bull. 2012;87:397\u2013405.","journal-title":"Brain Res Bull"},{"key":"398_CR89","doi-asserted-by":"publisher","first-page":"67658","DOI":"10.1371\/journal.pone.0067658","volume":"8","author":"D Colle","year":"2013","unstructured":"Colle D, Santos DB, Moreira ELG, Hartwig JM, dos Santos AA, Zimmermann LT, et al. Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. PLoS ONE. 2013;8:67658.","journal-title":"PLoS ONE"},{"key":"398_CR90","doi-asserted-by":"crossref","unstructured":"De Paula Nascimento-Castro C, Wink AC, Da F\u00f4nseca VS, Bianco CD, Winkelmann-Duarte EC, Farina M, et al. Antidepressant Effects of probucol on early-symptomatic YAC128 transgenic mice for Huntington\u2019s disease. Neural Plast. 2018;2018.","DOI":"10.1155\/2018\/4056383"},{"key":"398_CR91","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"398_CR92","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","volume":"48","author":"T Cukierman","year":"2005","unstructured":"Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia. 2005;48:2460\u20139.","journal-title":"Diabetologia"},{"key":"398_CR93","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","volume":"5","author":"GJ Biessels","year":"2006","unstructured":"Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64\u201374.","journal-title":"Lancet Neurol"},{"key":"398_CR94","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.2337\/db10-0539","volume":"59","author":"W Xu","year":"2010","unstructured":"Xu W, Caracciolo B, Wang HX, Winblad B, B\u00e4ckman L, Qiu C, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes. 2010;59:2928\u201335.","journal-title":"Diabetes"},{"issue":"12","key":"398_CR95","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.2337\/dc13-0143","volume":"36","author":"C Moran","year":"2013","unstructured":"Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, et al. Brain atrophy in type 2 diabetes regional distribution and influence on cognition. Diabetes Care. 2013;36(12):4036\u201342.","journal-title":"Diabetes Care"},{"key":"398_CR96","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2213-8587(13)70088-3","volume":"2","author":"GJ Biessels","year":"2014","unstructured":"Biessels GJ, Strachan MWJ, Visseren FLJ, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014;2:246\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"398_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.001","author":"RO Roberts","year":"2014","unstructured":"Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, Baertlein L, et al. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement. 2014;10(1):18-26.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"398_CR98","doi-asserted-by":"crossref","unstructured":"Ceretta LB, R\u00e9us GZ, Abelaira HM, Ribeiro KF, Zappellini G, Felisbino FF, et al. Increased oxidative stress and imbalance in antioxidant enzymes in the brains of alloxan-induced diabetic rats. Exp Diabetes Res. 2012;2012.","DOI":"10.1155\/2012\/302682"},{"key":"398_CR99","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0022-2143(03)00110-0","volume":"142","author":"Y Aliciguzel","year":"2003","unstructured":"Aliciguzel Y, Ozen I, Aslan M, Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med. 2003;142:172\u20137.","journal-title":"J Lab Clin Med"},{"key":"398_CR100","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1046\/j.1464-5491.2000.00259.x","volume":"17","author":"IC West","year":"2000","unstructured":"West IC. Radicals and oxidative stress in diabetes. Diabetic Med. 2000;17:171\u201380.","journal-title":"Diabetic Med"},{"key":"398_CR101","doi-asserted-by":"crossref","unstructured":"Muriach M, Flores-Bellver M, Romero FJ, Barcia JM. Diabetes and the brain: Oxidative stress, inflammation, and autophagy. Oxid Med Cell Longev. 2014;2014.","DOI":"10.1155\/2014\/102158"},{"key":"398_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8227(02)00005-0","volume":"57","author":"SI Gorogawa","year":"2002","unstructured":"Gorogawa SI, Kajimoto Y, Umayahara Y, Kaneto H, Watada H, Kuroda A, et al. Probucol preserves pancreatic \u03b2-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2002;57:1\u201310.","journal-title":"Diabetes Res Clin Pract"},{"key":"398_CR103","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1538\/expanim.52.317","volume":"52","author":"A Takatori","year":"2003","unstructured":"Takatori A, Ohta E, Inenaga T, Horiuchi K, Ishii Y, Itagaki SI, et al. Protective effects of probucol treatment on pancreatic \u03b2-cell function of SZ-induced diabetic APA hamsters. Exp Anim. 2003;52:317\u201327.","journal-title":"Exp Anim"},{"key":"398_CR104","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3109\/0886022X.2012.718711","volume":"34","author":"S Duan Bin","year":"2012","unstructured":"Duan Bin S, Liu GL, Wang YH, Zhang JJ. Epithelial-to-mesenchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats. Renal Fail. 2012;34:1244\u201351.","journal-title":"Renal Fail"},{"key":"398_CR105","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/j.intimp.2021.108397","volume":"102","author":"K Derangula","year":"2022","unstructured":"Derangula K, Javalgekar M, Kumar Arruri V, Gundu C, Kumar Kalvala A, Kumar A. Probucol attenuates NF-\u03baB\/NLRP3 signalling and augments Nrf-2 mediated antioxidant defence in nerve injury induced neuropathic pain. Int Immunopharmacol. 2022;102:108397.","journal-title":"Int Immunopharmacol"},{"key":"398_CR106","doi-asserted-by":"crossref","unstructured":"Liu HW, Luo Y, Zhou YF, Chen ZP. Probucol Prevents Diabetes-Induced Retinal Neuronal Degeneration through Upregulating Nrf2. Biomed Res Int. 2020;2020.","DOI":"10.1155\/2020\/3862509"},{"key":"398_CR107","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s10792-019-01130-8","volume":"39","author":"X Zhou","year":"2019","unstructured":"Zhou X, Ai S, Chen Z, Li C. Probucol promotes high glucose-induced proliferation and inhibits apoptosis by reducing reactive oxygen species generation in M\u00fcller cells. Int Ophthalmol. 2019;39:2833\u201342.","journal-title":"Int Ophthalmol"},{"key":"398_CR108","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4155\/tde-2019-0052","volume":"10","author":"A Mooranian","year":"2019","unstructured":"Mooranian A, Zamani N, Takechi R, Al-Sallami H, Mikov M, Golo\u010dorbin-Kon S, et al. Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Ther Deliv. 2019;10:563\u201371.","journal-title":"Ther Deliv"},{"key":"398_CR109","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4155\/tde-2018-0033","volume":"9","author":"JC Mamo","year":"2018","unstructured":"Mamo JC, Lam V, Al-Salami H, Brook E, Mooranian A, Nesbit M, et al. Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. Ther Del. 2018;9:703\u20139.","journal-title":"Ther Del"},{"key":"398_CR110","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s12035-016-9747-z","volume":"54","author":"DB Santos","year":"2017","unstructured":"Santos DB, Colle D, Moreira ELG, Hort MA, Godoi M, LeDouaron G, et al. Succinobucol, a non-statin hypocholesterolemic drug, prevents premotor symptoms and nigrostriatal neurodegeneration in an experimental model of Parkinson\u2019s disease. Mol Neurobiol. 2017;54:1513\u201330.","journal-title":"Mol Neurobiol"},{"key":"398_CR111","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbr.2016.02.023","volume":"305","author":"RP Ribeiro","year":"2016","unstructured":"Ribeiro RP, Santos DB, Colle D, Naime AA, Gon\u00e7alves CL, Ghizoni H, et al. Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: a model on the dissociation of bradykinesia from hypokinesia. Behav Brain Res. 2016;305:30\u20136.","journal-title":"Behav Brain Res"},{"key":"398_CR112","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.mito.2013.01.005","volume":"13","author":"D Colle","year":"2013","unstructured":"Colle D, Santos DB, Hartwig JM, Godoi M, Braga AL, Farina M. Succinobucol versus probucol: Higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro. Mitochondrion. 2013;13:125\u201333.","journal-title":"Mitochondrion"},{"key":"398_CR113","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s12035-014-9086-x","volume":"53","author":"D Colle","year":"2016","unstructured":"Colle D, Santos DB, Hartwig JM, Godoi M, Engel DF, de Bem AF, Braga AL, et al. Succinobucol, a lipid-lowering drug, protects against 3-nitropropionic acid-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y cells via upregulation of glutathione levels and glutamate cysteine ligase activity. Mol Neurobiol. 2016;53:1280\u201395.","journal-title":"Mol Neurobiol"},{"key":"398_CR114","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s12035-020-01956-9","volume":"57","author":"DC Bueno","year":"2020","unstructured":"Bueno DC, Canto RFS, de Souza V, Andreguetti RR, Barbosa FAR, Naime AA, et al. New probucol analogues inhibit ferroptosis, improve mitochondrial parameters, and induce glutathione peroxidase in HT22 cells. Mol Neurobiol. 2020;57:3273\u201390.","journal-title":"Mol Neurobiol"},{"key":"398_CR115","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1080\/10715762.2021.2017912","volume":"55","author":"AA Naime","year":"2021","unstructured":"Naime AA, Barbosa FAR, Bueno DC, Curi Pedrosa R, Canto RFS, Colle D, et al. Prevention of ferroptosis in acute scenarios: an in\u00a0vitro study with classic and novel anti-ferroptotic compounds. Free Radic Res. 2021;55:1062\u201379.","journal-title":"Free Radic Res"},{"key":"398_CR116","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1021\/acschemneuro.3c00138","volume":"14","author":"MT Jacques","year":"2023","unstructured":"Jacques MT, de Souza V, Barbosa FAR, Faria Santos Canto R, Lopes SC, Prediger RD, et al. Novel probucol analogue, 4,4\u2032-Diselanediylbis (2,6-di-tert-butylphenol), prevents oxidative glutamate neurotoxicity in vitro and confers neuroprotection in a rodent model of ischemic stroke. ACS Chem Neurosci. 2023;14:2857\u201367.","journal-title":"ACS Chem Neurosci"},{"key":"398_CR117","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1007\/s12035-018-0939-6","volume":"55","author":"RL Quispe","year":"2018","unstructured":"Quispe RL, Canto RFS, Jaramillo ML, Barbosa FAR, Braga AL, de Bem AF, et al. Design, synthesis, and in vitro evaluation of a novel probucol derivative: protective activity in neuronal cells through GPx upregulation. Mol Neurobiol. 2018;55:7619\u201334.","journal-title":"Mol Neurobiol"},{"key":"398_CR118","doi-asserted-by":"publisher","first-page":"10123","DOI":"10.1073\/pnas.95.17.10123","volume":"95","author":"O Cynshi","year":"1998","unstructured":"Cynshi O, Kawabe Y, Suzuki T, Takashima Y, Kaise H, Nakamura M, et al. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc Natl Acad Sci U S A. 1998;95:10123\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"398_CR119","doi-asserted-by":"publisher","first-page":"40497","DOI":"10.1074\/jbc.M104882200","volume":"276","author":"W Takabe","year":"2001","unstructured":"Takabe W, Kodama T, Hamakubo T, Tanaka K, Suzuki T, Aburatani H, et al. Anti-atherogenic antioxidants regulate the expression and function of proteasome \u03b1-type subunits in human endothelial cells. J Biol Chem. 2001;276:40497\u2013501.","journal-title":"J Biol Chem"},{"key":"398_CR120","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/10715769900300071","volume":"30","author":"K M\u00fcller","year":"1999","unstructured":"M\u00fcller K, Carpenter KLH, Freeman MA, Mitchinson MJ. Antioxidant BO-653 and human macrophage-mediated LDL oxidation. Free Radic Res. 1999;30:59\u201371.","journal-title":"Free Radic Res"},{"key":"398_CR121","first-page":"342","volume":"4","author":"CQ Meng","year":"2003","unstructured":"Meng CQ. BO-653. Chugai. Curr Opin Investig Drugs. 2003;4:342\u20136.","journal-title":"Curr Opin Investig Drugs"},{"key":"398_CR122","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.1021\/jm049685u","volume":"47","author":"CQ Meng","year":"2004","unstructured":"Meng CQ, Somers PK, Hoong LK, Zheng XS, Ye Z, Worsencroft KJ, et al. Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases. J Med Chem. 2004;47:6420\u201332.","journal-title":"J Med Chem"},{"key":"398_CR123","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1124\/jpet.104.080804","volume":"313","author":"C Kunsch","year":"2005","unstructured":"Kunsch C, Luchoomun J, Chen XL, Dodd GL, Karu KS, Meng CQ, et al. AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression. J Pharmacol Exp Ther. 2005;313:492\u2013501.","journal-title":"J Pharmacol Exp Ther"},{"key":"398_CR124","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1084\/jem.20052321","volume":"203","author":"BJ Wu","year":"2006","unstructured":"Wu BJ, Kathir K, Witting PK, Beck K, Choy K, Li C, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med. 2006;203:1117\u201327.","journal-title":"J Exp Med"},{"key":"398_CR125","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2337\/diab.42.8.1179","volume":"42","author":"MB Johnson","year":"1993","unstructured":"Johnson MB, Heineke EW, Rhinehart BL, Sheetz MJ, Barnhart RL, Robinson KM. MDL 29311 antioxidant with marked lipid-and glucose-lowering activity in diabetic rats and mice. Diabetes. 1993;42:1179\u201386.","journal-title":"Diabetes"},{"key":"398_CR126","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0026-0495(94)90251-8","volume":"43","author":"MJ Sheetz","year":"1994","unstructured":"Sheetz MJ, Barnhart RL, Jackson RL, Robinson KM. MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein. Metabolism. 1994;43:233\u201340.","journal-title":"Metabolism"},{"key":"398_CR127","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/pharmaceutics13081223","volume":"13","author":"SR Wagle","year":"2021","unstructured":"Wagle SR, Kovacevic B, Ionescu CM, Walker D, Jones M, Carey L, et al. Pharmacological and biological study of microencapsulated probucol-secondary bile acid in a diseased mouse model. Pharmaceutics. 2021;13:1223.","journal-title":"Pharmaceutics"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-024-00398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-024-00398-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-024-00398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:05:49Z","timestamp":1705921549000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-024-00398-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1186\/s40035-024-00398-w","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"5 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}